FacebookTwitterRedditEmail

Opioids for Depression? Not So Fast Says An FDA Advisory Committee

Photo Source Cindy Shebley | CC BY 2.0

The mental illness “franchise” has been very good to Pharma. While it could not “grow” the number of people with actual schizophrenia, it hassuccessfully grown those diagnosed with amorphous “schizoaffective” and bipolar disorders and, of course, depression.

Thanks to Pharma’s everyone-is-mentally-ill ploy, buoyed by the Pharma-funded writers of the Diagnostic and Statistical Manual of Mental Disorders, an estimated one quarter of the population now takes psych drugs. Gone are the days when bad moods were attributed to problems with finance, romance, jobs, housing, family, marriages and health.

Especially lucrative to Pharma is its concoction of “treatment resistant” depression which allows expensive psych drugs to be added to antidepressants while side-stepping why the aggressively advertised SSRIs aren’t effective on their own. (And whether the patient was ever really depressed.) The resulting “cocktails” are exceedingly hard for patients to quit––with new drugs added to treat the side effects of other drugs––and what is the original “mental illness” versus the drug effects is almost impossible to distinguish. Adding expensive psych drugs for “treatment resistant” depression has become such a common, profitable practice for Pharma, prescribing only one drug is now dismissed as just “monotherapy.”

The latest attempt to cash in on “treatment resistant” depression is by the Dublin-based biopharma company Alkermes. It hopes to jump start revenues with a “treatment resistant” depression drug candidate that combines the opioid buprenorphine (used to treat opioid addiction) with samidorphan, an opioid blocker to counteract the abuse potential of buprenorphine.

In hearings on November 1, Alkermes representatives tried to sell their drug candidate against antipsychotic drugs currently FDA-approved to be added for “treatment resistant” depression like quetiapine (Seroquel) and aripiprazole (Abilify) because those drugs add weight in patients and opioids don’t.

But Alkermes’ “two wrongs make a right” argument convinced few at the hearings in the middle of our current opioid addiction epidemic which takes over a hundred lives a day. All opioid drugs have abuse potential noted Stephanie Fox-Rawlings of National Center for Health Research during the open mike section and people with depression are especially prone to substance abuse.

Nor were advisory committee impressed with Alkermes’ effectiveness and safety data which was so weak it extrapolated positive results from only “one patient” observed a committee member and which used unaccepted, questionable study designs.

As always happens when new, expensive drug candidates come before an FDA advisory committee, Pharma was well represented by open mike speakers. In addition to those actually flown in and paid for by Alkermes, representatives from the Pharma-funded Depression & Bipolar Support Alliance and the Pharma-funded  American Foundation for Suicide Prevention made trite, tear-jerking pleas. Without a new buprenorphine/samidorphan drug, there will be more suicides ventured one speaker omitting the hundreds whose suicides are causedby psych drugs according to thousands of published reports.

If insurance doesn’t cover this new drug, patients who can’t afford it will suffer said another open mike speaker, exposing in one sentence how Pharma hijacks our health care costs with its 4 and 5-digit brand-name drug pricing racket.

However, despite the well-oiled Pharma game plan that gets expensive and often ineffective and unsafe drugs approved and the shameless Pharma plants, this FDA advisory committee decided in a 20-3 vote there was insufficient evidence that the new drug works. Normally the FDA follows its advisory committees decisions––let’s hope it does in this case.

More articles by:

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

bernie-the-sandernistas-cover-344x550
Weekend Edition
February 14, 2020
Friday - Sunday
Andrew Levine
Mayor Mike, Worse Than Mayor Pete
Bruce E. Levine
“Sublime Madness”: Anarchists, Psychiatric Survivors, Emma Goldman & Harriet Tubman
Jeffrey St. Clair
Roaming Charges: Leader of the Pack
Jennifer Matsui
The Doomsday Cuckoo Clock
Paul Street
Things Said in Confidence to 4000 Close Friends This Week
Jonathan Cook
Even With Corbyn Gone, Antisemitism Threats Will Keep Destroying the UK Labour Party
Thomas Klikauer
Cambridge Analytica: a Salesgirl’s Report
Joseph Natoli
Vichy Democrats vs. the Master Voice
David Rosen
Sanders vs. the Establishment Democrats: McGovern All Over Again?
Louis Proyect
Marx, Lincoln and Project 1619
Robert Hunziker
Amazon Onslaught
Russell Mokhiber
NPR and the Escalating Attack on Single-Payer Health Care
Ramzy Baroud
Breaking with Washington: Arabs and Muslims Must Take a United Stance for Palestine
Mike Miller
Race and Class: Overcoming the Divides
Michael Brennan
Timeline: How the DNC Manipulated 2016 Presidential Race 
Jacob G. Hornberger
U. S. Lies and Deaths in Afghanistan
Rev. William Alberts
Trump Served Up Projection at the National Prayer Breakfast
Nick Pemberton
The Overwhelming Sex Appeal Of Bernie Sanders
David Swanson
Why This Election Is Different
Dan Bacher
Western States Petroleum Association Tops CA Lobbying Expenses with $8.8 Million Spent in 2019
Christopher Ketcham
The Medium Warps the Message Straight to Our Extinction
Erik Molvar
Trump’s Gutting of NEPA Will Cut the Public Out of Public Lands Decisions
William Kaufman
Tulsi Gabbard: A Political Postmortem
Colin Todhunter
Menace on the Menu in Post-EU Britain
Gregory Elich
Mnangagwa’s Neoliberal Assault on the Zimbabwean People
Ron Jacobs
The Lies of Industry and the Liars Who Sell Them
Binoy Kampmark
Subverting the Blacklist: Kirk Douglas’s Modest Contribution
Tom Engelhardt
The War in Questions: Making Sense of the Age of Carnage
Peter Certo
Who’s Afraid of Socialism?
Brett Wilkins
Dresden, February 1945
Missy Comley Beattie
You’re a Lying, Dog-Faced Pony Soldier
Thomas Knapp
Yes, the ERA Has Been Ratified
Medea Benjamin - Nicolas J. S. Davies
Can the World’s Second Superpower Rise From the Ashes of Twenty Years of War?
Manuel García, Jr.
A Short History of Humanity’s Future
Leonard C. Goodman
The Iowa Fallout and the Democrats’ Shadowy Plot to Stop Sanders
Nilofar Suhrawardy
Delhi Polls: A Storm Over Winner’s “Religious” Acts!
Saad Hafiz
The Unending Human Tragedy in Syria
Jacob Levich
Ocasio-Cortez to Constituents on Bolivian Coup: Drop Dead
Nicky Reid
The Buttigieg Delusion
Gary Leupp
Gramsci and You: an Open Letter to Mayor Pete
Kollibri terre Sonnenblume
Black America and the Presidents
John Kendall Hawkins
50th Anniversary of Abbie Hoffman’s Intro to STB
Susan Block
Rush Limbaugh Gets Medal for Being the King of Creeps
David Yearsley
Better in Dolby
Peter Harrison
Money is Our Assonance: Seven Short Poems
FacebookTwitterRedditEmail